Essex Bio-Technology reports strong half-year performance with profit and revenue gains

Essex Bio-Technology Limited reported a consolidated turnover of HK$876.5 million for the six months ended June 30, 2025, a 5.8% increase from HK$828.5 million in the prior year. Profit for the period rose by 3.8% to HK$163.4 million, up from HK$157.4 million. The company declared an interim dividend of HK$0.07 per ordinary share for the period.

The Ophthalmology segment contributed HK$417.4 million to turnover, a 10.6% increase, while the Surgical segment generated HK$448.9 million, growing by 1.0%. The combined turnover from the bFGF Series biologics represented approximately 83.5% of the total turnover. Total R&D expenditures for the period were approximately HK$66.5 million, with HK$44.8 million capitalized.

As of June 30, 2025, total assets stood at HK$3,233.8 million, with cash and cash equivalents of HK$640.5 million. The gearing ratio was 29.7%. The company also advanced its SkQ1 Product and Anti-VEGF Licensed Product, with significant investments in these areas.